Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for tough lymphoma in japanese study

NCT ID NCT04533581

Ongoing Disease control Sponsor: Kyowa Kirin Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 study tests an oral drug called ME-401 in 61 Japanese adults with a slow-growing form of non-Hodgkin's lymphoma that has returned or not responded to at least two prior treatments. The drug is taken daily for the first two months, then on a weekly schedule. Researchers are checking how well it shrinks tumors and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ME-401 (a PI3K inhibitor taken orally)
What this could lead to
If successful, this could provide a new treatment option for Japanese patients with a hard-to-treat form of lymphoma that has come back after other therapies.
What could go wrong
This is a small, early-phase study (61 people) with no comparison group. The drug may not work well enough or could cause side effects. It is also limited to Japanese patients, so results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INDOLENT B-CELL NON-HODGKIN'S LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

indolent B-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INDOLENT B-CELL NON-HODGKIN'S LYMPHOMA

Contacts and locations

Locations

  • Aichi Cancer Center Hospital

    Nagoya, Aichi-ken, Japan

  • Akita University Hospital

    Akita, Japan

  • Anjo Kosei Hospital

    Anjo, Aichi-ken, Japan

  • Aomori Prefectural Central Hospital

    Aomori, Japan

  • Chiba Cancer Center

    Chiba, Japan

  • Chugoku Central Hospital

    Fukuyama, Hiroshima, Japan

  • Gunma University Hospital

    Maebashi, Gunma, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan

  • Ishikawa Prefectural Central Hospital

    Kanazawa, Ishikawa-ken, Japan

  • Japanese Red Cross Kyoto Daini Hospital

    Kyoto, Japan

  • Japanese Red Cross Nagoya Daini Hospital

    Nagoya, Aichi-ken, Japan

  • Jichi Medical University Hospital

    Shimotsuke, Tochigi, Japan

  • Kagoshima University Hospital

    Kagoshima, Japan

  • Kameda Medical Center

    Kamogawa, Chiba, Japan

  • Kindai University Hospital

    Sayama, Osaka, Japan

  • Kurashiki Central Hospital

    Kurashiki, Okayama-ken, Japan

  • Kyushu University Hospital

    Fukuoka, Japan

  • Mie University Hospital

    Tsu, Mie-ken, Japan

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan

  • National Hospital Organization Kumamoto Medical Center

    Kumamoto, Japan

  • National Hospital Organization Kyushu Medical Center

    Fukuoka, Japan

  • National Hospital Organization Nagoya Medical Center

    Nagoya, Aichi-ken, Japan

  • National Hospital Organization Shikoku Cancer Center

    Matsuyama, Ehime, Japan

  • Okayama University Hospital

    Okayama, Japan

  • Osaka University Hospital

    Suita, Osaka, Japan

  • Saitama Medical University International Medical Center

    Hidaka, Saitama, Japan

  • The Cancer Institute Hospital Of JFCR

    Koto-ku, Tokyo, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

  • Tokyo Metropolitan Komagome Hospital

    Bunkyo-ku, Tokyo, Japan

  • Tottori University Hospital

    Yonago, Tottori, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.